This company listing is no longer active
Oxford Cannabinoid Technologies Holdings Past Earnings Performance
Past criteria checks 0/6
Oxford Cannabinoid Technologies Holdings has been growing earnings at an average annual rate of 23.6%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually.
Key information
23.6%
Earnings growth rate
23.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -217.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Oxford Cannabinoid Technologies Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 23 | 0 | -4 | 3 | 0 |
| 31 Jul 23 | 0 | -5 | 3 | 0 |
| 30 Apr 23 | 0 | -6 | 3 | 0 |
| 30 Apr 22 | 0 | -5 | 3 | 0 |
Quality Earnings: 0CB is currently unprofitable.
Growing Profit Margin: 0CB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 0CB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 0CB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0CB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.1%).
Return on Equity
High ROE: 0CB has a negative Return on Equity (-217.39%), as it is currently unprofitable.